Clinical trialsCompany release

Acrivon adds oral JAK1 inhibitor ACR-525 as ACR-368 interim analysis nears

🇺🇸 Acrivon Therapeutics, Inc. (ACRV) · Mon 16 Nov 2026

The US oncology biotech reported Q3 2026 results, reporting an immunology acquisition, early ACR-2316 data plans, and cash of $77.8 million expected to last into Q4 2027.

Acrivon Therapeutics reported its third-quarter 2026 results on 16 November, alongside news that it has acquired ACR-525, an oral JAK1 inhibitor that is ready to enter Phase 2 development. The company plans to target eosinophilic esophagitis first.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): Acrivon Therapeutics, Inc. ↗

Article written by VigiEye from the official source (Acrivon Therapeutics, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →